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Antiretroviral Medication
Diversion Among
HIV-Positive Substance
Abusers in South Florida
Hilary L. Surratt, PhD, Steven P. Kurtz, PhD,
Theodore J. Cicero, PhD, Catherine O’Grady,
MPH, and Maria A. Levi-Minzi, MA
The high cost of life-saving anti-
retroviral (ARV) therapy for HIV rep-
resents an expense that impedes
accessibility and affordability by
patients. This price structure also
appears to motivate the diversion
of ARVs and the targeting of HIV-
positive patients by pill brokers in
the illicit market. Our field research
with indigent, HIV-positive sub-
stance abusers links ARV diversion
to high levels of competing needs,
including psychiatric disorders, HIV
stigma, and homelessness. Inter-
ventions to reduce diversion must
address the needs of highly vulner-
able patients. (Am J Public Health.
2013;103:1026–1028. doi:10.2105/
AJPH.2012.301092)
Medication adherence is critical in the man-
agement of many chronic illnesses, including
HIV.1 Antiretroviral (ARV) nonadherence
increases the risk of treatment failure, drug
resistance, and disease transmission.2 Our re-
cently completed field research among HIV-
positive patients in urban south Florida docu-
mented modest levels of ARV adherence and
a related, yet understudied, phenomenon: the
diversion of ARV medications. Diversion—the
unlawful channeling of regulated pharmaceu-
ticals from legal sources to illicit markets3—has
typically been studied in relation to prescrip-
tion opioids and other medications with sig-
nificant abuse potential.4 Nevertheless, the
diversion of ARVs by patients is apparent in
south Florida5 and has direct implications for
nonadherence, making it a critical issue for
patient care and public health. We examined
factors that affect vulnerability to ARV diversion
among highly marginalized HIV-positive
individuals.
METHODS
Guided by targeted sampling in geographic
areas with high HIV prevalence and poverty
indices,6 we used direct outreach to recruit
indigent HIV-positive substance abusers in
south Florida between 2010 and 2012. Re-
search staff distributed study cards and flyers
in street venues and HIV service organizations.
We enrolled approximately equal numbers of
users diverting their personal ARVs (n = 251)
and of those not doing so (n = 252); because
diverters had a lower average recruitment rate,
recruitment of the full sample of diverters took
24% longer than recruitment of the comparable
sample of nondiverters. Eligibility criteria were
as follows: age 18 years or older, cocaine or
heroin use 12 or more times in the prior 3
months, documented HIV-positive status, and
current ARV prescription. In addition, diverters
reported that they had diverted ARVs at least
once in the prior 3 months. Research staff
conducted systematic screening to verify eligibil-
ity; 2112 individuals were screened, 599 met
study eligibility criteria, and 503 were enrolled.
The primary reason for nonenrollment (84%)
was repeated failure to present for the interview.
Following informed consent, participants com-
pleted a single face-to-face interview based on the
Global Appraisal of Individual Needs (GAIN)7
instrument, which assessed demographics, sub-
stance use, substance dependence as measured by
the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Revised Edition (DSM-IV-R), and
mental health status. Standardized instruments
assessed HIV diagnosis and treatment history,8
attitudes toward HIV care providers,9 health
literacy,10 HIV-related stigma,11 ARV knowledge
and attitudes,12,13 and ARV adherence14; a new
instrument assessed ARV diversion. Participants
received a $30 stipend upon interview comple-
tion. Bivariate logistic regressionmodels examined
the factors associated with ARV diversion in this
sample; we included significant predictors from
the bivariate analyses in the multivariate model.
RESULTS
Median age of participants was 46 years;
59.4% were male. Of the participants, 55.3%
met DSM-IV-R criteria for past-year substance
dependence, 81.4% reported monthly income
below $1000, and 39.2% were homeless in
the prior 3 months. Diverters reported a median
of 7 lifetime episodes of ARV diversion. Self-
reported ARV adherence in the past week was
95% or better among 54.1% of participants;
compared with nondiverters, diverters had sig-
nificantly lower odds of achieving 95% adher-
ence (odds ratio = 0.26; 95% confidence inter-
val = 0.18, 0.37; P £ .001). Table 1 displays
the bivariate and multivariate predictors of ARV
diversion. Male gender, severe depression,
severe anxiety, substance dependence, recent
homelessness, and high HIV-related stigma
were each associated with increased odds of
diverting prescribed ARV medications. The
odds of diversion were lower among partici-
pants reporting higher HIV-related treatment
knowledge and higher health literacy, and
among those achieving 95% ARV adherence.
In the multivariate model, recent homeless-
ness and male gender were associated with
increased odds of ARV diversion; higher HIV-
related treatment knowledge, better adher-
ence, and higher health literacy remained as
significant protective factors.
DISCUSSION
The diversion of noncontrolled prescrip-
tion drugs garners less attention and re-
sources from law enforcement, the health
practitioner and scientific communities, poli-
cymakers, educators, and industry than the
diversion of controlled substances. Neverthe-
less, diversion of noncontrolled substances,
such as ARVs, has clear implications for the
integrity of the medication supply chain, for
patient safety, and for public health.15 Our
data show that indigent substance-abusing
patients face challenges with ARV adherence
and, moreover, that nonadherence is linked
to the diversion of ARVs. The targeting of
indigent, street-based, HIV-positive patients
by pill brokers or “collectors” who offer small
sums for patients’ monthly supplies of ARV
medications appears to be common in south
Florida5,16; even 37.4% of nondiverters
reported being approached for this purpose
(H. L. S., unpublished data, 2011). The pricing
structure of ARV medications makes them
highly profitable in the illicit market,17 in
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effect incentivizing diversion and the target-
ing of HIV-positive individuals with high
levels of competing needs. In our sample, men
appeared to be especially vulnerable to ARV
diversion. Although the reason is unclear,
males were more likely to report recent
homelessness, which may increase their ex-
posure to street-level pill brokers and dealers.
Interventions to enhance medication adherence
and reduce diversion should be tailored for
the most vulnerable, homeless HIV-positive
individuals. Individual-level, practitioner-
based interventions should aim at instilling
knowledge of ARV treatment regimens
and health literacy factors; HIV treatment
specialists and other health practitioners
should be aware of the potential for ARV
diversion to better support their patients.
Housing insecurity requires increased atten-
tion at a structural level to reduce the
exploitation of vulnerable HIV-positive
individuals. j
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Missed Opportunities for
Hepatitis C Testing in
Opioid Treatment
Programs
Jemima A. Frimpong, PhD, MPH
HCV has surpassed HIV as a
cause of death in the United
States and is particularly prevalent
among injection drug users. I ex-
amined the availability of on-site
HCV testing in a nationally repre-
sentative sample of opioid treat-
ment programs. Nearly 68% of
these programs had the staff re-
quired for HCV testing, but only
34% offered on-site testing. Avail-
ability of on-site testing increased
only slightly with the proportion of
injection drug users among clients.
The limited HCV testing services in
opioid treatment programs is a key
challenge to reducing HCV in the
US population. (Am J Public Health.
2013;103:1028–1030. doi:10.2105/
AJPH.2012.301129)
HCV recently surpassed HIV as a cause of
death in the United States.1,2 Approximately
3.2 million people nationwide are living with
chronic hepatitis, but most are unaware of their
status because of limited opportunities for
testing.3---6 Persons who inject drugs are par-
ticularly at risk for HCV infection as a result of
sharing and reusing of needles.4,7 The esti-
mated prevalence of antibodies to HCV (anti-
HCV) among injection drug users ranges from
35% to 65%.8 The Centers for Disease Control
and Prevention (CDC) thus recommends rou-
tine HCV testing for all current or former
injection drug users.1,9 Offering HCV testing
services in drug abuse treatment programs
could help increase HCV case finding and
reduce transmission.10,11 It could also help
foster the adoption of preventive behaviors:
knowledge of one’s anti-HCV status may in-
deed lead to safer injection practices (or other
protective behaviors).12,13
I examined the availability of on-site HCV
testing services in opioid treatment programs
(i.e., physical facilities with resources dedicated
specifically to treating opiate dependence with
methadone, buprenorphine, or both).14,15 Opi-
oid treatment programs treat both persons who
inject drugs and people who have opiate addic-
tion but do not inject drugs. The current recom-
mended HCV testing protocol requires the col-
lection of venous blood, performed by qualified
staff (i.e., phlebotomists).16 However, the avail-
ability of (1) human resources required to offer
HCV testing services and (2) on-site HCV
testing services at opioid treatment programs
nationwide is not known. I examined relations
among the availability of on-site HCV testing
services, human resources for HCV testing, and
the proportion of injection drug users among
opioid treatment program clients.
METHODS
I analyzed data from the 2011 National
Drug Abuse Treatment System Survey
(NDATSS).14,17,18 In total, a nationally repre-
sentative sample of 200 opioid treatment pro-
grams completed the survey. Twenty-two opi-
oid treatment programs refused to participate,
and 90 initially screened were unable to
complete interviews. A response rate of 87%
was calculated with the Council of American
Survey Research Organization method.19 I
found no significant differences between re-
sponders and nonresponders.
I used 3 data elements from the 2011
NDATSS: (1) the proportion of injection drug
users among clients of an opioid treatment
program, (2) the presence of staff who perform
blood collection, and (3) the availability of HCV
testing services on site. I calculated the pro-
portion of opioid treatment programs with
human resources capacity and on-site HCV
testing. I categorized opioid treatment pro-
grams by the prevalence of injection drug users
among their clients (0%---24%, 25%---49%,
50%---74%, or 75%---100%). I used logistic
regression with controls for opioid treatment
program size (i.e., total number of clients in past
year) to examine the association between hu-
man resources capacity and on-site HCV test-
ing and the proportion of injection drug users
among clients. I report predicted probabilities
from these regressions. I used the simple Wald
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